At the same time the Trump administration has vowed to attack rising drug costs, the Department of Commerce has released a report that some academics and consumer advocates argue would restrain the ability of the federal government to limit “excessive” prescription drug prices.

In a lengthy document that largely mirrors a draft report leased late last year, the department’s National Institute of Standards and Technology offers suggestions for modernizing technology transfer and innovation, and proposed several ideas for maximizing returns on taxpayer investment in R&D.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy